Blood Viscosity, Finger Systolic Pressure and Effect of Dazoxiben Treatment in Primary Vasospastic Disease
- 18 January 1984
- journal article
- research article
- Published by Uppsala Medical Society in Upsala Journal of Medical Sciences
- Vol. 89 (3) , 213-219
- https://doi.org/10.3109/03009738409179501
Abstract
Whole blood viscosity, plasma viscosity, erythrocyte deformability, and finger systolic pressure (FSP) were measured in ten patients with primary vasospastic (Raynaud's) disease before and after a controlled double-blind prospective trial involving dazoxiben (a thromboxane inhibitor, Pfizer). Five of the patients were assigned to dazoxiben and five to placebo. Before treatment, the FSP at 10 °C in the patient groups was significantly lower than that in a normal reference group, but all rheologic variables, measured at 37 and 10 °C, were normal. There was no significant correlation between FSP and rheology. Dazoxiben did not yield any subjective relief or give any objective effect.This publication has 9 references indexed in Scilit:
- UK-37,248, A novel, selective thromboxane synthetase inhibitor with platelet anti-aggregatory and anti-thrombotic activityThrombosis Research, 1981
- ADMINISTRATION TO MAN OF UK-37,248-01, A SELECTIVE INHIBITOR OF THROMBOXANE SYNTHETASEThe Lancet, 1981
- Blood viscosity, Raynaud's phenomenon and the effect of fibrinolytic enhancementBritish Journal of Surgery, 1981
- Hyperviscosity and Thrombotic Changes in Idiopathic and Secondary Raynaud's SyndromeBritish Journal of Haematology, 1980
- Raynaud phenomena and finger systolic pressure during coolingScandinavian Journal of Clinical and Laboratory Investigation, 1978
- Raynaud's Disease: Reduced Hand Blood Flows with Normal Blood ViscosityAustralian and New Zealand Journal of Medicine, 1978
- ABNORMAL BLOOD VISCOSITY IN RAYNAUD'S PHENOMENONThe Lancet, 1976
- BLOOD VISCOSITY AND RAYNAUD'S DISEASEThe Lancet, 1965
- RAYNAUDʼS DISEASEThe Lancet Healthy Longevity, 1932